Burrows L, Tartter P, Aufses A
Cancer Detect Prev. 1987;10(5-6):361-9.
Blood transfusions have been shown to induce immunomodulative alterations in the transfusee such as changes in suppressor to helper T-cell ratio. They also have a beneficial antirejection effect in renal transplant recipients. To determine if blood transfusions play a role in tumor recurrence, the records of 177 transfused and 118 untransfused patients with Dukes stages B2, C1, or C2 operated on between June 1976 and July 1979 were examined. Ninety-five percent of untransfused patients were recurrence free at the end of 1 year compared to 86% of perioperatively transfused patients (P greater than .005), and this difference persisted for the 5 years of the study. Transfused patients in any of the pathological stages had lower recurrence-free rates in every postoperative year. Critical statistical analysis in this retrospective study indicates that the administration of blood is an important factor in the development of recurrence, and the increased incidence of recurrence is unrelated to the extent of operation or to the clinical need for transfusions before or during surgery.
输血已被证明会在受血者体内引发免疫调节性改变,比如抑制性T细胞与辅助性T细胞比例的变化。输血对肾移植受者也有有益的抗排斥作用。为了确定输血是否在肿瘤复发中起作用,研究人员检查了1976年6月至1979年7月间接受手术的177例输血患者和118例未输血患者的记录,这些患者的肿瘤分期为杜克B2期、C1期或C2期。1年后,95%的未输血患者无复发,而围手术期输血患者的这一比例为86%(P>0.005),并且在该研究的5年期间这种差异一直存在。处于任何病理分期的输血患者在术后各年的无复发率都较低。这项回顾性研究的关键统计分析表明,输血是复发发生的一个重要因素,复发率增加与手术范围或手术前或手术期间输血的临床需求无关。